This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: June 27, 2012
Last updated: July 11, 2015
Last verified: June 2015
This study investigated the effects of LCZ696 on insulin sensitivity, lipolysis, and oxidative metabolism in obese hypertensive subjects.

Condition Intervention Phase
Hypertension Concurrent Obesity Drug: LCZ696 Drug: amlodipine Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: A Randomized, Double-blind, Parallel Group Study to Evaluate Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Change From Baseline in Insulin Sensitivity Index [ Time Frame: baseline, 8 weeks ]
    The insulin sensitivity index was assessed by hyperinsulinemic euglycemic clamp (HEGC). A positive change from baseline indicates improvement.

Secondary Outcome Measures:
  • Local Adipose Tissue Lipolysis, Glycerol Concentrations [ Time Frame: 57 days ]
    Lipolysis was assessed through subcutaneous adipose tissue microdialysis. The actual measure type is adjusted geometric mean.

  • Oxidative Metabolism [ Time Frame: 57 days ]
    Oxidative metabolism was assessed by indirect calorimetry.

  • Number of Participants With Adverse Events, Serious Adverse Events and Deaths [ Time Frame: 8 weeks ]
    Adverse event monitoring was conducted throughout the study.

Enrollment: 98
Study Start Date: October 2012
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LCZ696
LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks
Drug: LCZ696
LCZ696 was provided as 400 mg tablets.
Drug: Placebo
Matching placebo to LCZ696 and amlodipine.
Active Comparator: amlodipine
amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks
Drug: amlodipine
amlodipine was provided as 5 mg tablets.
Drug: Placebo
Matching placebo to LCZ696 and amlodipine.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent must be obtained before any study assessment is performed.
  • Males and females of non-childbearing potential ≥ 18 years of age.
  • Subjects with mild to moderate essential hypertension,

    • Untreated subjects must have a mean seated SBP (msSBP) ≥ 130 mmHg and < 180 mmHg at screening.
    • Pre-treated subjects must have a msSBP ≤ 160 mmHg at screening and < 180 mmHg at the end of the washout period.
  • Waist circumference ≥ 102 cm (men) and ≥ 88 cm (women);

Exclusion criteria:

  • Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer; or longer if required by local regulations.
  • History of angioedema, drug-related or otherwise
  • History of hypersensitivity to LCZ696, amlodipine, or drugs of similar chemical classes.
  • Severe hypertension (grade 3 of WHO classification; msDBP ≥100 mmHg and/or msSBP ≥ 180 mmHg) at screening or at the end of the washout period.
  • Type 1 or Type 2 diabetes mellitus.
  • Dyslipidemia requiring pharmacological therapy with a fibrate or nicotinic acid.
  • Concomitant use of anti-hypertensives, anti-diabetics, or drugs with effects on glucose or lipid metabolism for the duration of the study.

Other protocol defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01631864

Novartis Investigative Site
Hannover, Germany, 30625
Novartis Investigative Site
Neuss, Germany, 41460
Novartis Investigative Site
Maastricht, Netherlands, 5800
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals Identifier: NCT01631864     History of Changes
Other Study ID Numbers: CLCZ696B2207
2012-002606-40 ( EudraCT Number )
Study First Received: June 27, 2012
Results First Received: July 11, 2015
Last Updated: July 11, 2015

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Hypertension, obesity, insulin sensitivity, lipolysis, LCZ696

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
LCZ 696
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Angiotensin Receptor Antagonists processed this record on September 21, 2017